mp.weixin.qq.com·· 11 hours agoScore80
INTerpath-001 Phase 3 Positive While BNT113 Plus Pembrolizumab Misses on PFS, Splitting mRNA Cancer Vaccine Results
In brief
Clinical results for mRNA cancer vaccines are diverging. The Phase 3 INTerpath-001 trial read out positive, while BNT113 combined with pembrolizumab failed to significantly improve PFS in first-line treatment.
Source: mp.weixin.qq.com · mp.weixin.qq.com